加科思-B（01167）今日盘中大涨5.56%，引发市场广泛关注。这一显著涨幅主要源于公司近期发布的2024年度业绩报告以及市场对其未来发展的乐观预期。
根据公司公告，加科思2024年全年营收达1.56亿元，同比增长145.2%。尽管公司仍处于亏损状态，但全年亏幅较去年同期大幅收窄43.4%至1.56亿元。值得注意的是，公司毛利同比增长高达4765.6%，这一显著增长主要得益于与艾力斯达成的9亿元里程碑合作协议。
更引人注目的是，加科思的首个重磅产品——KRAS G12C抑制剂戈来雷塞预计将于2025年上半年获批上市。这标志着公司即将进入价值兑现期，有望为公司带来稳定的现金流。此外，公司在KRAS通路的深耕布局，包括处于临床一期的泛KRAS抑制剂等项目，也为未来发展提供了强劲动力。多家券商看好加科思的发展前景，认为公司估值仍处于较低水平，未来仍有上涨空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.